Antagonism of the nicotine-induced changes of the striatal dopamine metabolism in mice by mecamylamine and pempidine
- 1 August 1988
- journal article
- research article
- Published by Springer Nature in Naunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie
- Vol. 338 (2) , 169-173
- https://doi.org/10.1007/bf00174865
Abstract
The ability of nicotinic receptor blockers, mecamylamine and pempidine, to antagonize the changes in striatal dopamine (DA) metabolism induced by repeated nicotine administration was studied. The contents of DA and its metabolites 3-methoxytyramine (3-MT), 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) were measured. Mice kept at 20–22°C were given nicotine, 3 mg/kg, s.c., four times, at 30 min intervals, and sacrificed 20 min after the last dose. Hexamethonium, 10 mg/kg, i.p., was administered at 30 min before the first nicotine dose in order to prevent the peripheral effects of nicotine. Mecamylamine, 0.6 or 10 mg/kg, i.p., and pempidine, 0.6 or 20 mg/kg, i.p., were given at 60 min before sacrifice. Mecamylamine and pempidine decreased clearly the striatal 3-MT content, which suggests that the nigrostriatal dopaminergic neurons are physiologically controlled by a stimulatory nicotinic mechanism. The repeatedly administered nicotine caused deep hypothermia, and increased the striatal DOPAC content but decreased the 3-MT and HVA contents. The small dose of mecamylamine, which was the only dose found to effectively antagonize the nicotine-induced hypothermia, antagonized the decrease of HVA content. The large but not the small doses of mecamylamine and pempidine antagonized the nicotine-induced increase of DOPAC content but none of the doses studied antagonized the decrease of 3-MT content. Thus it seems that nicotine decreases the 3-MT content by a mechanism distinct from the mechanism mediating the increase of the DOPAC content. The decreased 3-MT content most probably results from desensitization of nicotinic cholinergic receptors (nAChR) and following decrease of cholinergic regulation of nigrostriatal dopaminergic neurons. The changed conformation of nAChR explains the inability of mecamylamine and pempidine to antagonize the nicotine-induced decrease of 3-MT content.This publication has 18 references indexed in Scilit:
- The nicotine-induced changes in striatal dopamine metabolism of mice depend on body temperatureBrain Research, 1986
- Acetylcholine Receptor: An Allosteric ProteinScience, 1984
- On the Significance of Endogenous 3‐Methoxytyramine for the Effects of Centrally Acting Drugs on Dopamine Release in the Rat BrainJournal of Neurochemistry, 1982
- NICOTINIC-CATECHOLAMINERGIC INTERACTIONS IN RAT-BRAIN - EVIDENCE FOR CHOLINERGIC NICOTINIC AND MUSCARINIC INTERACTIONS WITH HYPOTHALAMIC EPINEPHRINE1982
- Central actions of nicotineMedicinal Research Reviews, 1982
- EFFECT OF MECAMYLAMINE ON THE FATE OF DOPAMINE IN STRIATAL AND MESOLIMBIC AREAS OF RAT BRAIN; INTERACTION WITH MORPHINE AND HALOPERIDOLBritish Journal of Pharmacology, 1978
- Nicotine-induced release of catecholamines from rat hippocampus and striatumBiochemical Pharmacology, 1978
- EFFECT OF NICOTINE ON CENTRAL CATECHOLAMINE NEURONS AND GONADOTROPIN-SECRETION .1. STUDIES IN MALE RAT1977
- 3-Methoxytyramine as an indicator of impulse-induced dopamine release in rat brain in vivoNaunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie, 1976
- Homovanillic acid concentration in rat brain: Effect of a choline acetyltransferase inhibitor and comparison with cholinergic and dopaminergic agentsNeuropharmacology, 1975